Issues and challenges for antiangiogenic therapies

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Angiogenesis is defined as the growth and proliferation of blood vessels from the existing vasculature, allowing a developing tissue to obtain the nutrients necessary to maintain growth. This fundamental mechanism underlies the processes of reproduction, development and repair and occurs in both normal and tumor tissues. Since this process is confined to rapidly growing tissues, and is quiescent in normal tissues, it was hypothesized by Folkman [1] that any therapeutic intervention that inhibited angiogenesis would be relatively specific to tumors, sparing normal tissue. The mechanisms by which tumors induce angiogenesis are complex. Tumors rapidly outgrow the capacity of the vasculature in their host tissue to provide nutrition and oxygenation, and are inherently hypoxic. In response to hypoxia, they produce a number of potent protein-mediators that stimulate the growth of new blood vessels. These angiogenic factors are not specific to tumors - they are produced by all tissues in response to hypoxia. Many of the mechanisms have been elucidated at a molecular level, and a number of ligands, receptors and signal-transduction pathways defined. Many of these represent potential targets for the development of novel therapeutic agents. Several drug candidates that target angiogenic mechanisms are currently being evaluated in breast cancer. The ultimate goal of all such development is to improve disease outcome, and to augment currently available therapies. However, the evaluation of these drug candidates in clinical studies is complex and requires a fundamental re-appraisal of conventional clinical trial methodology and the application of advanced bioscientific technology to facilitate understanding of the complex pharmacology that they may produce.

Original languageEnglish
JournalBreast Cancer Research and Treatment
Volume75
Issue numberSUPPL. 1
StatePublished - Oct 2002

Fingerprint

Neoplasms
Therapeutics
Blood Vessels
Growth
Drug Evaluation
Angiogenesis Inducing Agents
Reproduction
Signal Transduction
Clinical Trials
Pharmacology
Breast Neoplasms
Ligands
Technology
Food
Pharmaceutical Preparations
Proteins
Hypoxia
Clinical Studies

Keywords

  • Antiangiogenic
  • Antitumor
  • Chemotherapy
  • Clinical
  • Endothelial
  • Preclinical

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Issues and challenges for antiangiogenic therapies. / Miller, Kathy.

In: Breast Cancer Research and Treatment, Vol. 75, No. SUPPL. 1, 10.2002.

Research output: Contribution to journalArticle

@article{3289234b24f040cb982979144e256e11,
title = "Issues and challenges for antiangiogenic therapies",
abstract = "Angiogenesis is defined as the growth and proliferation of blood vessels from the existing vasculature, allowing a developing tissue to obtain the nutrients necessary to maintain growth. This fundamental mechanism underlies the processes of reproduction, development and repair and occurs in both normal and tumor tissues. Since this process is confined to rapidly growing tissues, and is quiescent in normal tissues, it was hypothesized by Folkman [1] that any therapeutic intervention that inhibited angiogenesis would be relatively specific to tumors, sparing normal tissue. The mechanisms by which tumors induce angiogenesis are complex. Tumors rapidly outgrow the capacity of the vasculature in their host tissue to provide nutrition and oxygenation, and are inherently hypoxic. In response to hypoxia, they produce a number of potent protein-mediators that stimulate the growth of new blood vessels. These angiogenic factors are not specific to tumors - they are produced by all tissues in response to hypoxia. Many of the mechanisms have been elucidated at a molecular level, and a number of ligands, receptors and signal-transduction pathways defined. Many of these represent potential targets for the development of novel therapeutic agents. Several drug candidates that target angiogenic mechanisms are currently being evaluated in breast cancer. The ultimate goal of all such development is to improve disease outcome, and to augment currently available therapies. However, the evaluation of these drug candidates in clinical studies is complex and requires a fundamental re-appraisal of conventional clinical trial methodology and the application of advanced bioscientific technology to facilitate understanding of the complex pharmacology that they may produce.",
keywords = "Antiangiogenic, Antitumor, Chemotherapy, Clinical, Endothelial, Preclinical",
author = "Kathy Miller",
year = "2002",
month = "10",
language = "English",
volume = "75",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Issues and challenges for antiangiogenic therapies

AU - Miller, Kathy

PY - 2002/10

Y1 - 2002/10

N2 - Angiogenesis is defined as the growth and proliferation of blood vessels from the existing vasculature, allowing a developing tissue to obtain the nutrients necessary to maintain growth. This fundamental mechanism underlies the processes of reproduction, development and repair and occurs in both normal and tumor tissues. Since this process is confined to rapidly growing tissues, and is quiescent in normal tissues, it was hypothesized by Folkman [1] that any therapeutic intervention that inhibited angiogenesis would be relatively specific to tumors, sparing normal tissue. The mechanisms by which tumors induce angiogenesis are complex. Tumors rapidly outgrow the capacity of the vasculature in their host tissue to provide nutrition and oxygenation, and are inherently hypoxic. In response to hypoxia, they produce a number of potent protein-mediators that stimulate the growth of new blood vessels. These angiogenic factors are not specific to tumors - they are produced by all tissues in response to hypoxia. Many of the mechanisms have been elucidated at a molecular level, and a number of ligands, receptors and signal-transduction pathways defined. Many of these represent potential targets for the development of novel therapeutic agents. Several drug candidates that target angiogenic mechanisms are currently being evaluated in breast cancer. The ultimate goal of all such development is to improve disease outcome, and to augment currently available therapies. However, the evaluation of these drug candidates in clinical studies is complex and requires a fundamental re-appraisal of conventional clinical trial methodology and the application of advanced bioscientific technology to facilitate understanding of the complex pharmacology that they may produce.

AB - Angiogenesis is defined as the growth and proliferation of blood vessels from the existing vasculature, allowing a developing tissue to obtain the nutrients necessary to maintain growth. This fundamental mechanism underlies the processes of reproduction, development and repair and occurs in both normal and tumor tissues. Since this process is confined to rapidly growing tissues, and is quiescent in normal tissues, it was hypothesized by Folkman [1] that any therapeutic intervention that inhibited angiogenesis would be relatively specific to tumors, sparing normal tissue. The mechanisms by which tumors induce angiogenesis are complex. Tumors rapidly outgrow the capacity of the vasculature in their host tissue to provide nutrition and oxygenation, and are inherently hypoxic. In response to hypoxia, they produce a number of potent protein-mediators that stimulate the growth of new blood vessels. These angiogenic factors are not specific to tumors - they are produced by all tissues in response to hypoxia. Many of the mechanisms have been elucidated at a molecular level, and a number of ligands, receptors and signal-transduction pathways defined. Many of these represent potential targets for the development of novel therapeutic agents. Several drug candidates that target angiogenic mechanisms are currently being evaluated in breast cancer. The ultimate goal of all such development is to improve disease outcome, and to augment currently available therapies. However, the evaluation of these drug candidates in clinical studies is complex and requires a fundamental re-appraisal of conventional clinical trial methodology and the application of advanced bioscientific technology to facilitate understanding of the complex pharmacology that they may produce.

KW - Antiangiogenic

KW - Antitumor

KW - Chemotherapy

KW - Clinical

KW - Endothelial

KW - Preclinical

UR - http://www.scopus.com/inward/record.url?scp=0036776755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036776755&partnerID=8YFLogxK

M3 - Article

VL - 75

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - SUPPL. 1

ER -